Over 30 years experience in nephrology understanding key pathological processes in chronic kidney disease and translating these to therapeutic molecules. Previously spent 10 years as Head of fibrotic remodelling at UCB taking zampilimab to Phase 2 for the treatment of chronic allograft nephropathy & 2.5 years as Head of Target Discovery at Mestag Therapeutics”